Presentation Information
[OE1-4]Differential effects of HLA-B*15:11 and HLA-A*31:01 on carbamazepine-induced cutaneous adverse reactions
○Koya Fukunaga1,2, Eri Tsukagoshi2, Maiko Kurata3, Yoshiko Mizukawa3, Hiroyuki Niihara4, Eishin Morita4, Yuko Watanabe5, Yukie Yamaguchi5, Hideaki Watanabe6, Saeko Nakajima7, Takashi Nomura7, Kenji Kabashima7, Tohyama Mikiko8, Hiroaki Azukizawa9, Hideo Asada9, Akito Hasegawa10, Natsumi Hama10, Takeshi Ozeki1, Yoichi Mashimo11, Akihiro Sekine11, Kayoko Matsunaga12, Yoichi Tanaka2, Ryosuke Nakamura2,13, Riichiro Abe10, Taisei Mushiroda1, Yoshiro Saito14 (1.Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, 2.Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan, 3.Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan, 4.Department of Dermatology, Faculty of Medicine, Shimane University, Shimane, Japan, 5.Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 6.Department of Dermatology, Showa University Northern Yokohama Hospital, Yokohama, Japan, 7.Department of Dermatology, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto, Japan, 8.Department of Dermatology, National Hospital Organization Shikoku Cancer Center, Japan, 9.Department of Dermatology, School of Medicine, Nara Medical University, Kashihara, Japan, 10.Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 11.Department of Public Health, Chiba University Graduate School of Medicine, Chiba, Japan, 12.Fujita Health University School of Medicine, Aichi, Japan, 13.Laboratory of Pharmaceutical Bioscience, Faculty of Pharmaceutical Sciences, Teikyo University, Tokyo, Japan, 14.National Institute of Health Sciences, Kawasaki, Japan)